Table 2.
Prevalence ratios for RAASia prescription from modified Poisson models with different levels of adjustment
| Model 1 | Model 2 | Model 3 | |
|---|---|---|---|
| Country (vs US) | |||
| Brazil | 1.27 (1.09,1.49) | 1.29 (1.12,1.49) | 1.29 (1.12,1.48) |
| France | 1.49 (1.32,1.68) | 1.41 (1.25,1.58) | 1.44 (1.29,1.62) |
| Germany | 1.53 (1.36,1.73) | 1.48 (1.31,1.66) | 1.51 (1.34,1.69) |
| Demographics | |||
| Age, per 10 y | 0.97 (0.96,0.99) | 0.96 (0.94,0.97) | |
| Female sex (vs male) | 0.96 (0.93,0.99) | 0.96 (0.93,0.99) | |
| CKD stage (vs stage 3b) | |||
| 3a | 1.00 (0.94,1.06) | 1.00 (0.95,1.05) | |
| 4 | 0.96 (0.92,1.00) | 0.96 (0.92,1.00) | |
| 5 | 0.70 (0.61,0.81) | 0.70 (0.61,0.80) | |
| Comorbidities (yes vs no) | |||
| Coronary artery disease | 0.99 (0.96,1.02) | ||
| Congestive heart failure | 0.94 (0.89,1.00) | ||
| Diabetes | 1.08 (1.04,1.12) | ||
| Hypertension | 1.52 (1.38,1.68) | ||
Abbreviations: ACEi, angiotensin‐converting enzyme inhibitors; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; RAASi, renin‐angiotensin‐aldosterone system inhibitors; US, United States.
a
Includes ACEi, ARB, direct renin inhibitors, and aldosterone receptor antagonists.